PR Newswire BiotechOriginal article
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors
emavusertibNeutral
AI Analysis
Summary
Curis, Inc. announced the pricing of an $8.5 million private placement, priced at-the-market under Nasdaq rules, with existing healthcare focused institutional investors. The company is developing emavusertib (CA-4948), an oral IRAK4 and FLT3 inhibitor.
Outcome Details
$8.5 million private placement priced at-the-market under Nasdaq rules with existing healthcare focused institutional investors
Importance:4/10
Sentiment:
-0.10
private placementofferingfinancingat-the-marketIRAK4FLT3small molecule
Related Companies
Read the original article
Published by PR Newswire Biotech on October 16, 2026 12:00 PM